Treatment of HCV infection with the novel NS3/4A protease inhibitors

Andrea De Luca, Claudia Bianco, Barbara Rossetti

Risultato della ricerca: Contributo in rivistaArticolo in rivista

24 Citazioni (Scopus)


HCV NS3/4A serine protease inhibitors are the first class of direct acting antivirals (DAA) introduced in clinical practice. The first generation agents, selective against HCV genotype 1, are used in association with pegylated interferons and ribavirin allowing increased cure rates at the price of increased toxicity, significant drug interactions and high risk of selecting mutants conferring cross-resistance to the entire class. A large number of second-wave HCV protease inhibitors are currently in clinical development. Advancements include higher potency, activity against a wider number of genotypes, improved tolerability, easier dosing schedules, although their genetic barrier to resistance remains low, especially for subtype 1a, except for the most recent grazoprevir and ACH-2684. The most relevant progress regards the combination with other classes of DAA allowing construction of interferon-free regimens of short duration, good tolerability with exceptionally high cure rates.
Lingua originaleEnglish
pagine (da-a)9-17
Numero di pagine9
RivistaCurrent Opinion in Pharmacology
Stato di pubblicazionePubblicato - 2014


  • Antiviral Agents
  • Drug Discovery3003 Pharmaceutical Science
  • Hepatitis C
  • Humans
  • Pharmacology
  • Protease Inhibitors
  • Viral Nonstructural Proteins


Entra nei temi di ricerca di 'Treatment of HCV infection with the novel NS3/4A protease inhibitors'. Insieme formano una fingerprint unica.

Cita questo